- Home
- LVTX vs LTRN Comparison
LVTX vs LTRN Comparison
Compare LVTX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- LTRN
- Stock Information
- Founded
- LVTX 2016
- LTRN 2013
- Country
- LVTX Netherlands
- LTRN United States
- Employees
- LVTX N/A
- LTRN N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- LTRN Health Care
- Exchange
- LVTX Nasdaq
- LTRN Nasdaq
- Market Cap
- LVTX 33.9M
- LTRN 36.0M
- IPO Year
- LVTX 2021
- LTRN 2020
- Fundamental
- Price
- LVTX $1.42
- LTRN $4.01
- Analyst Decision
- LVTX Hold
- LTRN Strong Buy
- Analyst Count
- LVTX 3
- LTRN 1
- Target Price
- LVTX $1.75
- LTRN $25.00
- AVG Volume (30 Days)
- LVTX 48.5K
- LTRN 546.1K
- Earning Date
- LVTX 08-19-2025
- LTRN 08-07-2025
- Dividend Yield
- LVTX N/A
- LTRN N/A
- EPS Growth
- LVTX N/A
- LTRN N/A
- EPS
- LVTX N/A
- LTRN N/A
- Revenue
- LVTX $4,990,000.00
- LTRN N/A
- Revenue This Year
- LVTX N/A
- LTRN N/A
- Revenue Next Year
- LVTX N/A
- LTRN N/A
- P/E Ratio
- LVTX N/A
- LTRN N/A
- Revenue Growth
- LVTX N/A
- LTRN N/A
- 52 Week Low
- LVTX $0.85
- LTRN $2.55
- 52 Week High
- LVTX $2.21
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- LVTX 52.65
- LTRN 56.09
- Support Level
- LVTX $1.33
- LTRN $3.73
- Resistance Level
- LVTX $1.67
- LTRN $4.43
- Average True Range (ATR)
- LVTX 0.13
- LTRN 0.46
- MACD
- LVTX 0.00
- LTRN -0.00
- Stochastic Oscillator
- LVTX 25.00
- LTRN 63.59
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.